The exploratory analysis for the efficacy and safety of Rikkunshito for appetite loss during the treatment with PEG-interferon and ribaviri
Not Applicable
- Conditions
- The patients with appetite loss during the treatment with PEG-interferon and ribavirin in the patients with hepatitis C
- Registration Number
- JPRN-UMIN000001924
- Lead Sponsor
- Department of Medicine and Clinical Oncolog, Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
The patients (1)after removal of their stomach (2)with heart failure or severe inflammation (3)with disorder in liver, gallbladder, or pancreas (4)with pregnancy, or breast-feeding now (5)with astrointestinal bleeding, mechanical ileus, perforation in gastrointestine (6)taking prohibited drug during trial (7) impossible to take a drug per oral (8)taking herbal medicine during trial (9)who are unsuitable judged by the responsible person
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method